Clinical Trial Update: Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluated the combination of nilotinib and RAD001 (everolimus) in patients with acute myeloid leukemia; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Everolimus (everolimus)
• Nilotinib (nilotinib)

Snippet

Sponsor: Technical University of Munich | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: COMPLETED